16667-57-5 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
Uridine, 2',3'-O-(1-methoxyethylidene)is utilized as a precursor for the synthesis of nucleoside analogs, which are essential for the development of new drugs with improved therapeutic properties. The chemical modification of uridine allows for the creation of more stable and bioavailable compounds, enhancing their effectiveness in treating various diseases and conditions.
Used in Medical Treatments:
The enhanced stability and bioavailability of Uridine, 2',3'-O-(1-methoxyethylidene)make it suitable for use in medical treatments, particularly in the development of nucleoside-based therapeutic agents. These analogs can target specific cellular processes and signaling pathways, offering potential benefits in the treatment of various diseases and disorders.
Used in Neurological and Metabolic Disorders Research:
Uridine, 2',3'-O-(1-methoxyethylidene)and its derivatives are being explored for their potential role in neurological and metabolic disorders. The modified uridine can influence various cellular processes and signaling pathways in the body, offering insights into the development of novel therapeutic strategies for the treatment of these conditions.
Used in Diagnostic Techniques:
The chemical properties of Uridine, 2',3'-O-(1-methoxyethylidene)also make it a promising candidate for use in diagnostic techniques. The enhanced stability and bioavailability of the molecule can improve the sensitivity and specificity of diagnostic assays, facilitating the early detection and monitoring of diseases and disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 16667-57-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,6,6 and 7 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 16667-57:
(7*1)+(6*6)+(5*6)+(4*6)+(3*7)+(2*5)+(1*7)=135
135 % 10 = 5
So 16667-57-5 is a valid CAS Registry Number.
